Can ebselen prevent cisplatin-induced ovarian damage?

  • Zeynep Soyman
  • Hafize Uzun
  • Nihan Bayindir
  • Mukaddes Esrefoglu
  • Birtan Boran
Gynecologic Endocrinology and Reproductive Medicine
  • 25 Downloads

Abstract

Purpose

The occurrence of ovarian damage is a major shortcoming in treating tumors with cisplatin (CP). The present study investigates the beneficial effects of ebselen—a seleno-organic compound with antioxidant and antiinflammatory properties—vis-à-vis CP-induced ovarian damage.

Methods

Twenty-eight adult female rats were divided into four study groups. Group 1 received no treatment. The rats in Groups 2, 3, and 4 were intraperitoneally administered CP (2 mg/kg/day) twice per week, for 5 weeks. Those in Group 2 received 0.3 ml saline (0.9% NaCl) intraperitoneally 60 min before each CP treatment, while those in Group 3 received 0.2 ml dimethyl sulfoxide (DMSO) and 0.3 ml saline intraperitoneally 60 min before each CP treatment. The rats in Group 4 were pretreated with an intraperitoneal injection of 15 mg/kg/day ebselen 60 min before each CP treatment. Ovarian tissue malondialdehyde (MDA), total nitric oxide (NOx), glutathione (GSH), Cu/Zn-superoxide dismutase (Cu/Zn-SOD), and catalase levels, as well as histopathological damage scores (HDSs) and serum antimullerian hormone (AMH) levels, were assessed.

Results

Cu/Zn-SOD and GSH levels were significantly higher, and MDA and NOx levels significantly lower, in Group 4 than in Groups 2 and 3. Pretreatment with ebselen significantly improved serum AMH levels, relative to Groups 2 and 3. Additionally, HDS values were significantly lower in Group 4 than in Groups 2 and 3.

Conclusions

Our results from using an experimental rat model of CP chemotherapy suggest that ebselen use may ameliorate ovarian damage by preventing oxidative injury.

Keywords

Anti-mullerian hormone Cisplatin Ebselen Oxidative stress Ovary 

Notes

Acknowledgments

This work was financially supported by the Research Fund of Istanbul Education and Research Hospital (Grant Number: 19.03.2015/64).

Author contributions

ZS was involved in management data analysis, intellectual idea, protocol development, data collection, writing and editing; HU was involved in data collection and writing; NB was involved in data collection and statistics; ME was involved in data collection and editing; BB was involved in data collection and management data analysis.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interests.

Ethical approval

The presented study was approved by the animal local ethics committee of Bezmialem Vakif University. All procedures performed in studies involving animals were in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.

References

  1. 1.
    Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K et al (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917–2931.  https://doi.org/10.1200/JCO.2006.06.5888 CrossRefPubMedGoogle Scholar
  2. 2.
    Yeh J, Kim B, Liang YJ, Peresie J (2006) Müllerian inhibiting substance as a novel biomarker of cisplatin-induced ovarian damage. Biochem Biophys Res Commun 348:337–344.  https://doi.org/10.1016/j.bbrc.2006.06.195 CrossRefPubMedGoogle Scholar
  3. 3.
    Yucebilgin MS, Terek MC, Ozsaran A, Akercan F, Zekioglu O, Isik E et al (2004) Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility. Aust N Z J Obstet Gynaecol 44:6–9.  https://doi.org/10.1111/j.1479-828X.2004.00143.x CrossRefPubMedGoogle Scholar
  4. 4.
    Morgan S, Lopes F, Gourley C, Anderson RA, Spears N (2013) Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. PLoS ONE 8:70117.  https://doi.org/10.1371/journal.pone.0070117 CrossRefGoogle Scholar
  5. 5.
    Deavall DG, Martin EA, Horner JM, Roberts R (2012) Drug induced oxidative stress and toxicity. J Toxicol 2012:645460.  https://doi.org/10.1155/2012/645460 CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Meng X, Chen H, Wang G, Yu Y, Xie K (2015) Hydrogen-rich saline attenuates chemotherapy-induced ovarian injury via regulation of oxidative stress. Exp Ther Med 10:2277–2282.  https://doi.org/10.3892/etm.2015.2787 CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Soylu Karapinar O, Pinar N, Özcan O, Atik Doğan E, Bayraktar S, Şahin H, Dolapçioğlu K (2017) The effect of dexpanthenol on experimentally induced ovarian ischaemia/reperfusion injury: a biochemical and histopathological evaluation. Arch Gynecol Obstet 295:777–784.  https://doi.org/10.1007/s00404-017-4287-y CrossRefPubMedGoogle Scholar
  8. 8.
    van Rooij IAJ, Broekmans FJM, te Velde ER, Fauser BCJM, Bancsi LFJMM, de Jong FH et al (2002) Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 17:3065–3071CrossRefPubMedGoogle Scholar
  9. 9.
    Anderson RA, Cameron DA (2011) Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 96:1336–1343.  https://doi.org/10.1210/jc.2010-2582 CrossRefPubMedGoogle Scholar
  10. 10.
    Parnham MJ, Sies H (2013) The early research and development of ebselen. Biochem Pharmacol 86:1248–1253.  https://doi.org/10.1016/j.bcp.2013.08.028 CrossRefPubMedGoogle Scholar
  11. 11.
    Singh N, Halliday AC, Thomas JM, Kuznetsova OV, Baldwin R, Woon EC et al (2013) A safe lithium mimetic for bipolar disorder. Nat Commun 4:1332.  https://doi.org/10.1038/ncomms2320 CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T et al (1998) Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 29:12–17CrossRefPubMedGoogle Scholar
  13. 13.
    Parnham M, Sies H (2000) Ebselen: prospective therapy for cerebral ischemia. Expert Opin Investig Drugs 9:607–619.  https://doi.org/10.1517/13543784.9.3.607 CrossRefPubMedGoogle Scholar
  14. 14.
    Yoshida M, Iizuka K, Terada A, Hara M, Nishijima H, Akinori et al (2000) Prevention of nephrotoxicity of cisplatin by repeated oral administration of ebselen in rats. Tohoku J Exp Med 191:209–220CrossRefPubMedGoogle Scholar
  15. 15.
    Kim SJ, Park C, Han AL, Youn MJ, Lee JH, Kim Y et al (2009) Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells. Hear Res 251:70–82.  https://doi.org/10.1016/j.heares.2009.03.003 CrossRefPubMedGoogle Scholar
  16. 16.
    Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F (2003) An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 182:12–20CrossRefPubMedGoogle Scholar
  17. 17.
    Tripathi DN, Jena GB (2008) Ebselen attenuates cyclophosphamide-induced oxidative stress and DNA damage in mice. Free Radic Res 42:966–977.  https://doi.org/10.1080/10715760802566558 CrossRefPubMedGoogle Scholar
  18. 18.
    Okhawa H, Ohshı N, Yagı K (1979) Assay or lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358CrossRefGoogle Scholar
  19. 19.
    Beutler E, Duran O, Kelly MB (1963) Improved method for the determination of blood glutathione. J Lab Clin Med 51:882–888Google Scholar
  20. 20.
    Sun Y, Oberly LW, Ying LA (1998) Simple method for clinical assay of superoxide dismutase. Clin Chem 34:497–500Google Scholar
  21. 21.
    Yasmineh WG, Kaur TP, Blazar BR, Theologides A (1995) Serum catalase as marker of graft-versus-host disease in allogenic bone marrow transplant recipients. Clin Chem 41:1574–1580PubMedGoogle Scholar
  22. 22.
    Witte AB, Anestal K, Jerremalm E, Ehrsson H, Arner ES (2005) Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 1:696–703.  https://doi.org/10.1016/j.freeradbiomed.2005.04.025 CrossRefGoogle Scholar
  23. 23.
    Carbone MC, Tatone C, Delle Monache S, Marci R, Caserta D, Colonna R (2003) Antioxidant enzymatic defences in human follicular fluid: characterization and age-dependent changes. Mol Hum Reprod 9:639–643CrossRefPubMedGoogle Scholar
  24. 24.
    Simone CB 2nd, Simone NL, Simone V, Simone CB (2007) Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med 13:22–28PubMedGoogle Scholar
  25. 25.
    Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB (2008) Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 100:773–783.  https://doi.org/10.1093/jnci/djn148 CrossRefPubMedGoogle Scholar
  26. 26.
    Lynch ED, Gu R, Pierce C, Kil J (2005) Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity. Anticancer Drugs 16:569–579CrossRefPubMedGoogle Scholar
  27. 27.
    Baldew GS, McVie JG, van der Valk MA, Los G, de Goeij JJM, Vermeulen NPE (1990) Selective reduction of cis-diamminedichloroplatinum (II) nephrotoxicity by ebselen. Cancer Res 50(21):7031–7036PubMedGoogle Scholar
  28. 28.
    Zhao R, Masayasu H, Holmgren A (2002) Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant. Proc Natl Acad Sci 99:8579–8584.  https://doi.org/10.1073/pnas.122061399 CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Dhanarajan R, Abraham P, Isaac B (2006) Protective effect of ebselen, a selenoorganic drug, against gentamicin-induced renal damage in rats. Basic Clin Pharmacol Toxicol 99:267–272.  https://doi.org/10.1111/j.1742-7843.2006.pto_474.x CrossRefPubMedGoogle Scholar
  30. 30.
    Meirow D (2000) Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 27:123–131CrossRefGoogle Scholar
  31. 31.
    Ozcelik B, Turkyilmaz C, Ozgun MT, Serin IS, Batukan C, Ozdamar S et al (2010) Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist. Fertil Steril 93:1609–1614.  https://doi.org/10.1016/j.fertnstert.2009.02.054 CrossRefPubMedGoogle Scholar
  32. 32.
    Erbaş O, Akman L, Yavaşoğlu A, Terek MC, Akman T, Taskiran D (2014) Oxytocin improves follicular reserve in a cisplatin-induced gonadotoxicity model in rats. Biomed Res Int 2014:703691.  https://doi.org/10.1155/2014/703691 PubMedCentralPubMedGoogle Scholar
  33. 33.
    Akdemir A, Zeybek B, Akman L, Ergenoglu AM, Yeniel AO, Erbas O et al (2014) Granulocyte-colony stimulating factor decreases the extent of ovarian damage caused by cisplatin in an experimental rat model. J Gynecol Oncol 25:328–333.  https://doi.org/10.3802/jgo.2014.25.4.328 CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Pan Y, Zhang L, Zhang X, Hu C, Liu R (2017) Biological and biomechanical analysis of two types of mesenchymal stem cells for intervention in chemotherapy-induced ovarian dysfunction. Arch Gynecol Obstet 295:247–252.  https://doi.org/10.1007/s00404-016-4224-5 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyMinistry of Health, Istanbul Education and Research HospitalIstanbulTurkey
  2. 2.Department of BiochemistryIstanbul University Cerrahpasa School of MedicineIstanbulTurkey
  3. 3.Department of Histology and EmbryologyBezmialem Vakif University School of MedicineIstanbulTurkey

Personalised recommendations